Glimepirid Hexal

Glimepirid Hexal is a prescription oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea used to manage blood glucose. It is marketed in the European Union and is typically supplied as tablets, with strength options that may vary by country. The product belongs to the antidiabetic, oral hypoglycemic therapeutic class and works by stimulating insulin release from pancreatic β‑cells in patients with type 2 diabetes.

Glimepirid Hexal is indicated for the treatment of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

- As monotherapy in patients newly diagnosed with type 2 diabetes. - As add‑on therapy to metformin when glycemic targets are not met. - In combination with other oral antidiabetic agents such as DPP‑4 inhibitors. - For patients who require a once‑daily oral hypoglycemic with a well‑established efficacy profile. - May be considered in individuals who prefer oral therapy over injectable insulin.

The safety profile of glimepiride includes a range of observed adverse events that vary in frequency and severity.

Common: - Low blood sugar (hypoglycemia), especially when meals are missed or dosing is excessive. - Weight gain due to increased insulin activity. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as rash, itching, or angioedema. - Hematologic abnormalities like leukopenia or thrombocytopenia.

Before prescribing Glimepirid Hexal, clinicians should evaluate several patient‑specific factors to minimize risk.

- Assess renal and hepatic function, as impairment can increase drug exposure. - Review history of hypoglycemia or adrenal insufficiency. - Use caution in elderly patients due to higher susceptibility to low blood sugar. - Evaluate cardiovascular status, especially if the patient has heart failure. - Consider pregnancy and lactation status; safety data are limited. - Monitor for signs of skin reactions or blood‑cell abnormalities during therapy.

Glimepirid Hexal can interact with other medicines, affecting blood glucose levels or drug metabolism.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma concentrations. - High‑dose salicylates that potentiate hypoglycemic effect.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can raise blood glucose and require dose adjustment. - Alcohol consumption, which can enhance hypoglycemia risk. - Anticoagulants, as hypoglycemia may affect INR stability.